Floatz logo

Tisagenlecleucel

Minimal Residual Disease

M.D. Anderson Cancer CenterCell therapyPhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
73/ 100

Competitive context

51 Active assets in the Minimal Residual Disease cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 4BB
FILGRASTIM
Masonic Cancer Center, University of Minnesota
Phase 2/3BB
NEPENTHE
The Institute of Molecular and Translational Medicine, Czech Republic
Phase 4B
LIDOCAINE
The Institute of Molecular and Translational Medicine, Czech Republic
Phase 4B
DEXAMETHASONE
Instituto do Cancer do Estado de São Paulo
Phase 4B

View all 50 →

Same molecule, other indications

Tisagenlecleucel is also rated in:

non-Hodgkin lymphomaDormant
BB
Indicative ·
66 / 100
View asset →
Diffuse Large B Cell LymphomaDormant
BB
Indicative ·
64 / 100
View asset →
B-cell Acute Lymphoblastic LeukemiaDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →